Magazine article Clinical Psychiatry News

Duloxetine Dampens Depression, Comorbid Pain. (Results of Three Trials)

Magazine article Clinical Psychiatry News

Duloxetine Dampens Depression, Comorbid Pain. (Results of Three Trials)

Article excerpt

SAN ANTONIO -- Duloxetine, a potent new serotonin and norepinephrine reuptake inhibitor, reduces the symptoms of major depressive disorder and decreases chronic, comorbid pain in depressed patients.

The results of three trials were presented in a poster session at the annual meeting of the Academy of Psychosomatic Medicine.

In an interview, Dr. John R. Hayes, a project team leader at Eli Lilly & Co., Indianapolis, said that the company would soon submit data on the drug to the Food and Drug Administration for approval.

In one randomized, placebo-controlled study involving 236 patients, the estimated response rate to once-daily, 60-mg doses of duloxetine, as measured by the Hamilton Depression Rating Scale, was 62%; the estimated remission rate was 44%. Both rates were significantly greater than the 29% response rate and 16% remission rate achieved with placebo.

In the same study, patients reported a significant reduction in overall pain and back pain compared with placebo, as measured by the visual analog scale. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.